RecruitingNCT07143513
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
Sponsor
Amgen
Enrollment
115 participants
Start Date
Aug 11, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The primary objective of this study is to characterize the safety profile of sotorasib.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Adult (≥ 18 years) as of the index date.
- KRAS p.G12C-mutated locally advanced or metastatic NSCLC.
- Received at least 1 dose of sotorasib.
- Receipt of at least 1 prior systemic therapy before use of sotorasib.
- Obtained ICF, if required.
Exclusion Criteria1
- Documentation of being a non-Chinese ethnicity.
Interventions
DRUGSotorasib
Participants will have received sotorasib orally daily until disease progression or unacceptable toxicity.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07143513
Related Trials
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
NCT0536331949 locations
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT0509813227 locations
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT07195695192 locations
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT0691707910 locations
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
NCT0693171734 locations